MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024

Tissue-based test volumes increase by 36%, liquid-based test volumes by 24%

Company raises 2024 revenue guidance to $87-89 million, representing 25% growth

Read more at globenewswire.com